Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Transfer of the Marketing Authorization for Topirolic Tablets and Acquisition of Related AssetsCounterpartyFuji Yakuhin Co., Ltd.
Disclosing companyMochida Pharmaceutical Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Procedures and assumptions
Management structure after acquisitionFrom 1 October 2026, Mochida Pharmaceutical is scheduled to become the marketing authorization holder for the product and conduct sales and information provision activities.
| Item | Details |
|---|---|
| Transaction name | Transfer of the Marketing Authorization for Topirolic Tablets and Acquisition of Related Assets |
| Counterparty name | Fuji Yakuhin Co., Ltd. |
| Contract Date | 19 August 2026 |
| Execution Date / Effective Date | On or after 1 October 2026 (scheduled) |
| Management structure after acquisition | From 1 October 2026, Mochida Pharmaceutical is scheduled to become the marketing authorization holder for the product and conduct sales and information provision activities. |
Items this document does not state (27)
Name of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to further expand treatment options for gout and hyperuricemia by providing this product in addition to Uris Tablets, and to contribute further to improving patients' quality of life through appropriate information provision activities for healthcare professionals, taking advantage of the strength of having both products, which have different mechanisms of action.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.